A method and breathing device for controlling ventilation support in cancer patients with isocarbonate hyperventilation and high concentration of oxygen.

Abstract

This invention proposes a control method and breathing device for ventilation support in cancer patients using isocarbonic hyperventilation with high-concentration oxygen. It relates to the field of medical device technology. The method includes: delivering high-concentration oxygen to the cancer patient for hyperventilation therapy, wherein the concentration range of the high-concentration oxygen is set to 60% to 100%, generating an initial hyperoxia ventilation state; real-time acquisition of the patient's end-tidal carbon dioxide partial pressure data to generate a dynamic carbon dioxide monitoring signal; by maintaining normal carbon dioxide levels, it effectively avoids hypocapnia and its physiological harm induced by traditional hyperventilation and hyperoxia therapy; on the one hand, it avoids the potential impact of hypocapnia on immune function; on the other hand, by maintaining normal CO2 levels, it avoids the tumor chemotherapy resistance that may be induced by a hypercapnic environment, allowing the adjuvant radiotherapy and chemotherapy of hyperoxia to be fully effective.

Description

Technical Field

[0001] This invention proposes a control method and breathing device for ventilation support of tumor patients with isocarbonate hyperventilation and high concentration of oxygen, which relates to the field of medical device technology. Background Technology

[0002] The hypoxic microenvironment within tumor tissues is a key factor in tumor progression, metastasis, and resistance to radiotherapy and chemotherapy. Studies have shown that increasing tissue oxygen partial pressure can effectively reverse hypoxia, enhance radiosensitivity, improve chemotherapeutic drug delivery, and activate anti-tumor immune responses. However, existing high-concentration oxygen therapy equipment faces two major challenges in clinical application: the risk of hypocapnia and the double-edged sword effect of hypercapnia.

[0003] The applicant's prior patent applications (CN121588323A, etc.) disclose a method and breathing device for maintaining isocarbonic hyperventilation using exogenous CO2 gas, capable of precisely maintaining PaCO2 at a physiological homeostasis of 35-45 mmHg. However, this technology has not yet been specifically applied to the field of ventilation support for cancer patients, particularly because its control method does not coordinate with the treatment windows of radiotherapy, chemotherapy, and immunotherapy, nor does it provide functions such as "pre-oxygenation" and "readiness signals" to ensure precise overlap between the hyperoxia homeostasis period and the treatment period. The timed ventilation function of conventional ventilators is merely a simple on / off control, unable to achieve precise matching with the time window of anti-tumor treatment or linkage with CO2 closed-loop control.

[0004] Therefore, developing a high-concentration oxygen ventilation support method and device that can safely and accurately maintain isocarbonate and coordinate with the timing of antitumor treatment has important clinical value. Summary of the Invention

[0005] This invention provides a method and apparatus for controlling ventilation support in cancer patients requiring isocarbonate hyperventilation with high oxygen concentrations, in order to solve the problems mentioned in the background section above: This invention proposes a method for controlling ventilation support in cancer patients requiring isocarbonate hyperventilation with high oxygen concentrations, the method comprising: S1. High-concentration oxygen is delivered to cancer patients for hyperventilation therapy, wherein the concentration range of the high-concentration oxygen is set to 60% to 100%, generating an initial hyperoxygenation state. S2. Real-time acquisition of patients' end-tidal carbon dioxide partial pressure data to generate dynamic carbon dioxide monitoring signals; S3. Compare and analyze the dynamic carbon dioxide monitoring signal with the preset isocarbonic acid target value range, wherein the preset target value range is 35-45 mmHg, and generate a carbon dioxide deviation assessment result. S4. Within the pre-oxygenation time window before the start of the first time window related to anti-tumor treatment, ventilation support is automatically started, and ventilation parameters and / or carbon dioxide supplementation of inhaled gas are automatically adjusted through the closed-loop feedback control system so that the patient has reached isocarbonate hyperoxia steady state when the first time window arrives. S5. After confirming that the patient has reached the isocarbonate hyperoxia steady state, a ready signal is generated and sent to the external anti-tumor treatment device, and ventilation support is continuously maintained within the first time window so that the patient's end-tidal carbon dioxide partial pressure is always maintained within the physiological steady state range of 35-45 mmHg.

[0006] This invention proposes a respiratory device for isocarbonate hyperventilation and high-concentration oxygen ventilation support in cancer patients to achieve the above-described method, the respiratory device comprising: High-concentration oxygen supply unit, used to deliver oxygen at a concentration of 60%-100% to cancer patients; The end-tidal carbon dioxide monitoring unit is used to collect patients' end-tidal carbon dioxide partial pressure data in real time. The control unit is connected to the monitoring unit, receives monitoring data and compares it with a preset target value, and generates an adjustment command based on the comparison result. The preset target value is 35-45 mmHg. An execution unit, connected to the control unit, automatically adjusts ventilation parameters and / or the carbon dioxide content of the inhaled gas according to the adjustment command; The timing control unit has built-in chemotherapy synchronization module, radiotherapy synchronization module and immunotherapy synchronization module, which store time window parameters for different treatment modes, so that the ventilation therapy of the device can be implemented within the treatment cycle of radiotherapy, chemotherapy or immunotherapy for cancer patients and cover at least part of the treatment period; the timing control unit is configured to generate and send a ready signal to external anti-tumor treatment equipment after confirming that the patient has reached isocarbonate hyperoxia steady state.

[0007] Compared with the applicant's prior patents such as CN121588323A, the core contribution of this invention lies in realizing pre-oxygenation, steady-state detection, ready signal transmission, and linkage with external anti-tumor treatment equipment through a timing control unit, which solves the clinical problem of precise matching between isocarbonate hyperoxia steady state and anti-tumor treatment window, rather than an improvement on the closed-loop control algorithm itself.

[0008] The beneficial effects of this invention are as follows: By maintaining normal carbon dioxide levels, it effectively avoids hypocapnia and its physiological harm induced by traditional hyperventilation and hyperoxia therapy; it employs multimodal closed-loop feedback control technology optimized for hyperoxia scenarios to achieve individualized, automated, and precise adjustment; more importantly, through a built-in dedicated timing control unit and a "ready" signal mechanism, it ensures that the hyperoxia steady-state period precisely overlaps with the chemotherapy drug exposure period, radiotherapy irradiation period, or immunotherapy window period, solving the clinical pain point of existing technologies that "have a steady state but use it at the wrong time," thus maximizing the combined treatment effect. Animal experimental data show that after adopting the timing synergistic control of this invention, the tumor inhibition rate of isocarbonate hyperoxia combined with chemotherapy increased from 50.2% in the randomized time-series group to 59.6% in the synchronous time-series group (p<0.05), demonstrating unexpected technical effects. Attached Figure Description

[0009] Figure 1 This is a diagram illustrating the steps of the method described in this invention; Figure 2 This is a schematic diagram of the device structure described in this invention; Figure 3 This is a schematic diagram of the timing control described in this invention. Detailed Implementation

[0010] The preferred embodiments of the present invention will be described below with reference to the accompanying drawings. It should be understood that the present invention provides a ventilation control method and apparatus for isocarbonate high-concentration oxygen, used to provide ventilation support for cancer patients to improve their oxygenation status and maintain normal hypercapnia, thereby creating favorable physiological conditions for concurrent anti-tumor therapy. The present invention is not directly used to treat tumors; its technical contribution lies in the ventilation control itself. Furthermore, the preferred embodiments described herein are for illustration and explanation only and are not intended to limit the present invention.

[0011] One embodiment of the present invention, such as Figure 1 As shown, a method for controlling ventilation support in cancer patients requiring isocarbonate hyperventilation with high oxygen concentrations is provided, the method comprising: S1. High-concentration oxygen is delivered to cancer patients for hyperventilation therapy, wherein the concentration range of the high-concentration oxygen is set to 60% to 100%, generating an initial hyperoxygenation state. S2. Real-time acquisition of patients' end-tidal carbon dioxide partial pressure data to generate dynamic carbon dioxide monitoring signals; S3. Compare and analyze the dynamic carbon dioxide monitoring signal with the preset isocarbonic acid target value range, wherein the preset target value range is 35-45 mmHg, and generate a carbon dioxide deviation assessment result. S4. Within the pre-oxygenation time window before the start of the first time window related to anti-tumor treatment, ventilation support is automatically started, and ventilation parameters and / or carbon dioxide supplementation of inhaled gas are automatically adjusted through the closed-loop feedback control system so that the patient has reached isocarbonate hyperoxia steady state when the first time window arrives. S5. After confirming that the patient has reached the isocarbonate hyperoxia steady state, a ready signal is generated and sent to the external anti-tumor treatment device, and ventilation support is continuously maintained within the first time window so that the patient's end-tidal carbon dioxide partial pressure is always maintained within the physiological steady state range of 35-45 mmHg.

[0012] The working principle of the above technical solution is as follows: The system first continuously delivers high-concentration oxygen (60%-100%) to cancer patients, rapidly increasing the partial pressure of oxygen in the patient's body and the oxygen content in tumor tissue, creating a basic oxygen environment for subsequent radiotherapy, chemotherapy, and immunotherapy. Simultaneously, this process completes treatment parameter locking, initial ventilation parameter calculation, multi-source mixed delivery, airway and sensor calibration, and baseline recording of vital signs, forming a stable, abnormal, and traceable initial hyperoxia ventilation state, providing a stable starting point for subsequent precise control. The system continuously collects end-tidal carbon dioxide partial pressure data from patients at a high-frequency sampling rate, simultaneously collecting multi-dimensional physiological information such as blood oxygen saturation, airway pressure, and respiratory flow. The raw signals are filtered, denoised, and digitally converted to remove interference factors such as coughing and positional changes. The processed data is then collected, spliced, and stored at fixed time intervals to form a continuous, smooth, and accurate dynamic carbon dioxide monitoring signal that reflects the patient's ventilation status, completely preserving the trend of carbon dioxide changes over time, providing a reliable data source for deviation analysis. The central control unit compares the real-time dynamic carbon dioxide monitoring signal with the preset isocarbonate target range of 35-45 mmHg point by point, calculates the carbon dioxide deviation value and rate of change, and simultaneously identifies external disturbances such as sudden changes in airway pressure, abnormal flow, and coughing. Combining the magnitude of the deviation, the trend of change, and the state of disturbance, it completes a comprehensive classification of ventilatory steady-state conditions, and finally outputs a carbon dioxide deviation assessment result including adjustment needs, adjustment direction, and adjustment priority, providing precise guidance for subsequent feedback adjustments. Based on this, the system automatically calculates the pre-oxygenation initiation time according to preset first-time window information related to anti-tumor treatment. Within the pre-oxygenation time window, the system automatically initiates ventilation support and, based on the carbon dioxide deviation assessment results, automatically matches an adjustment strategy suitable for the hyperoxia ventilation scenario. It performs combined adjustments to ventilation parameters such as ventilation frequency, tidal volume, and inspiratory-to-expiratory ratio, or controls the carbon dioxide supply and adjusts the dead space volume in the ventilation circuit. The system weightedly integrates the real-time calculated feedback adjustments with the initial ventilation setpoints to eliminate ventilation fluctuations caused by parameter abrupt changes. The optimized parameters are then converted into electrical control signals and sent to the ventilation actuator, ultimately generating a dynamic carbon dioxide steady-state maintenance command. This ensures a smooth and continuous adjustment process, allowing the patient to reach isocarbonyl hyperoxia steady-state by the time the first time window arrives. The system continuously corrects the hyperoxia ventilation output according to the dynamic carbon dioxide steady-state maintenance command, constantly calibrating ventilation parameters and gas ratios to keep the patient's end-tidal carbon dioxide partial pressure consistently within the physiological steady-state range of 35-45 mmHg. Once the system confirms that the patient has reached a steady state of isocarbonate hyperoxia, it immediately generates and sends a "ready" signal to external anti-tumor treatment devices (such as chemotherapy pumps, radiotherapy devices, and immunotherapy infusion pumps). This signal can take at least one form, such as a level signal, serial communication command, wireless communication message, medical device communication protocol message, or digital pulse signal, to trigger the external treatment device to synchronously start anti-tumor treatment.Throughout the treatment process, the system monitors the safety boundaries of inhaled carbon dioxide concentration, blood oxygen saturation, and airway pressure. Abnormal parameters automatically trigger alarms and degrade the operating level. In the simultaneous combined treatment mode, ventilation control is executed according to a preset timing window, ensuring that the hyperoxia steady-state period completely overlaps with the chemotherapy infusion, radiotherapy irradiation, and immunotherapy drug administration periods. This ultimately creates an isocarbonic hyperoxia ventilation state, avoiding tissue hypoxia caused by hypocarbonate and mitigating the protective effect of hypercarbonate on tumor cells, maximizing the synergistic effect of hyperoxia and anti-tumor therapy. Furthermore, this embodiment details the timing-coordinated control process of the method and chemotherapy.

[0013] Patient information: Male, 62 years old, stage IIIB lung adenocarcinoma, planned to receive chemotherapy regimen of "pemetrexed + cisplatin".

[0014] Treatment plan: Using the device of this invention, the target oxygen concentration is set to 80%, the target ETCO2 range is 38-42 mmHg, the treatment duration is 4 hours, and the "synchronous combined treatment mode" is activated.

[0015] Comparative experimental data: Set up the following experimental groups: The standard hyperoxia plus chemotherapy group (no CO2 supplementation, chemotherapy was randomized): tumor inhibition rate 46.7%±10.5%, PaCO2 approximately 32 mmHg (hypocarbonylation) Isocolic hyperoxia group (no chemotherapy, isocolic ventilation only): tumor inhibition rate 29.3%±15.4%, PaCO2 approximately 40 mmHg Isonic acid + chemotherapy randomized group (isonic acid hyperoxia, chemotherapy randomized): tumor inhibition rate 50.2% ± 10.0%, PaCO2 approximately 39.5 mmHg Isonic acid + concurrent chemotherapy group (this invention) (isocarbonate hyperoxia, synergistic chemotherapy timing): tumor inhibition rate 59.6%±10.5%, PaCO2 approximately 40.2 mmHg The results showed that under isocarbonate hyperoxia conditions, adding sequential synergistic control (pre-oxygenation → steady-state detection → ready signal → synchronous start-up) significantly increased the tumor inhibition rate from 50.2% to 59.6% (p<0.05), confirming that sequential synergistic control has unexpected technical effects.

[0016] The effects of the above technical solution are as follows: By continuously delivering high-concentration oxygen to cancer patients for ventilation therapy, the oxygen partial pressure level in both the patient's body and the tumor site can be increased, improving the hypoxic microenvironment at the tumor site. Collecting and tracking the patient's end-tidal carbon dioxide partial pressure data throughout the treatment process improves the real-time performance and precision of ventilation control, reducing the lag in parameter adjustments. Comparing and analyzing the monitoring data with the target range improves the completeness of deviation identification and reduces deviations from the safe ventilation range. Automatically adjusting ventilation parameters and gas ratios based on deviation results improves the stability of carbon dioxide level control, avoiding hypocapnia caused by over-ventilation and preventing reduced cerebral blood flow or tissue hypoxia due to abnormal carbon dioxide fluctuations. Maintaining the end-tidal carbon dioxide partial pressure within the physiological homeostatic range ensures the positive effects of hyperoxia therapy while mitigating the protective effects of a hypercapnia on tumor cells, reducing the risk of resistance to radiotherapy, chemotherapy, and immunotherapy, minimizing physiological disturbances during treatment, and improving the overall safety and synergistic effect of the treatment. Furthermore, by setting a pre-oxygenation time window and automatically initiating ventilation support before anti-tumor treatment, this ensures that the patient is in an optimal isocarbonate hyperoxia steady state when the treatment window arrives, addressing the clinical pain point of existing technologies where "steady state is achieved but the timing is incorrect." By generating and sending multi-form "ready" signals to external anti-tumor treatment devices, intelligent linkage between the respiratory device and chemotherapy, radiotherapy, and immunotherapy equipment is achieved, ensuring precise overlap between the hyperoxia steady state period and the anti-tumor treatment window, significantly enhancing the combined treatment effect. Animal experimental data show that after adopting the time-series synergistic control of this invention, the tumor inhibition rate of isocarbonate hyperoxia combined with chemotherapy increased from 50.2%±10.0% in the randomized time-series group to 59.6%±10.5% in the synchronous time-series group (p<0.05), demonstrating unexpected technical effects.

[0017] In one embodiment of the present invention, S1 includes: S11. Based on the basic information of the cancer patient, including age, weight, height, underlying diseases, tumor type and stage, and the proposed combined radiotherapy, chemotherapy or immunotherapy regimen, the system completes the preset and locking of personalized treatment parameters, sets the high concentration oxygen concentration in the range of 60%-100%, sets the target value of end-tidal carbon dioxide partial pressure in the normal physiological range of 35-45 mmHg, and selects the continuous mode, intermittent mode or simultaneous combined treatment mode to complete the full parameter configuration before treatment; S12. Based on the patient's individualized physiological data and preset minute ventilation requirements, the control module's built-in algorithm automatically calculates and generates initial ventilation parameters, including ventilation rate, tidal volume, inspiratory-to-expiratory ratio, and initial airway pressure threshold, to provide a standardized starting point for subsequent stable ventilation. The built-in algorithm is based on the patient's weight, ideal weight, and preset minute ventilation, using the formula: Tidal volume = Ideal weight × 8-10 mL / kg, Respiratory rate = Preset minute ventilation / Tidal volume. The initial CO2 supplementation flow rate is estimated based on the mass balance equation: VCO2 = VA × (FiCO2 - 0.03%), where VA is alveolar ventilation.

[0018] S13. Control the high-pressure oxygen source, air source and optional carbon dioxide source to enter the gas mixer in a preset ratio. After being humidified by the humidifier, the high concentration of oxygen is delivered to the patient through the inhalation circuit to establish the initial high oxygen ventilation state. S14. The system completes the gas path sealing check and sensor zero point calibration to ensure that the end-tidal carbon dioxide monitoring, blood oxygen monitoring, pressure monitoring and flow monitoring functions are all in normal working order, with no air leakage, pipe blockage or abnormal signal. S15. Record the patient's baseline vital signs data at the initial moment. The baseline vital signs data includes the initial end-tidal carbon dioxide value, blood oxygen saturation, heart rate and respiratory rate, which serve as a reference benchmark for subsequent adjustment and efficacy evaluation.

[0019] The working principle and effects of the above technical solution are as follows: By combining multiple basic patient information to lock in treatment parameters, the suitability of ventilation therapy can be improved, reducing the risks caused by mismatches between parameter settings and patient condition. Automatic generation of initial ventilation parameters through algorithms improves the accuracy of parameter output and reduces errors caused by manual settings. Proportionally mixed and humidified gas delivery from multiple sources improves ventilation comfort and enhances the stability of the initial hyperoxia state. Gas path detection and sensor calibration improve the reliability of monitoring data and prevent leaks, blockages, or signal anomalies from affecting the treatment process. Recording initial vital sign baseline data improves the reference accuracy of subsequent adjustments and efficacy assessments, providing a stable starting point for overall ventilation control, reducing physiological discomfort caused by parameter fluctuations, preventing deviations from the safe range in the early stages of treatment, and overall improving the safety and standardization of the treatment initiation phase.

[0020] In one embodiment of the present invention, step S12 includes: Extract individualized physiological data of patients, extract preset minute ventilation requirements, complete the fusion processing of the two types of information, and generate ventilation demand data to be calculated; The ventilation demand data to be calculated is imported into the built-in algorithm of the control module, and the numerical iteration processing inside the algorithm is completed to generate the basic calculation results of ventilation parameters. The basic calculation results of ventilation parameters are graded and filtered, retaining values ​​related to ventilation frequency and tidal volume to generate the first set of ventilation sub-parameters. Supplement the basic calculation results of ventilation parameters, obtain the relevant values ​​of the inspiratory-expiratory ratio and the relevant values ​​of the initial airway pressure threshold, and generate the second set of ventilation sub-parameters. Integrate the first group of ventilation sub-parameters with the second group of ventilation sub-parameters, complete the parameter combination and format unification, and generate initial ventilation parameters adapted to the patient's condition.

[0021] The working principle and effects of the above technical solution are as follows: Integrating patient physiological data and ventilation requirements to form the basis of calculation improves the completeness of data input and reduces calculation bias caused by missing information. Importing data into the algorithm for iterative processing improves the accuracy of ventilation parameter calculations and reduces errors caused by manual estimation. Hierarchical screening and extraction of different ventilation sub-parameters enhances the rationality of parameter composition and avoids the impact of chaotic parameter combinations on subsequent ventilation control. Integrating multiple sub-parameters and standardizing their format improves the standardization of initial ventilation parameters and reduces system response anomalies caused by inconsistent parameter formats. This allows initial ventilation settings to be tailored to the individual patient's condition and provides standardized support for subsequent stable ventilation, avoiding excessive ventilation fluctuations during the treatment initiation phase and improving the overall stability and safety of the treatment process.

[0022] In one embodiment of the present invention, S2 includes: S21. Using a mainstream or bypass end-tidal carbon dioxide sensor, continuously and in real time collect end-tidal carbon dioxide partial pressure data during the patient's exhalation process at a sampling frequency of not less than 10Hz, and completely capture the dynamic change curve of carbon dioxide concentration during the respiratory cycle. S22. Simultaneously, the patient's blood oxygen saturation signal is collected through a finger clip pulse oximeter, and real-time airway pressure, inspiratory and expiratory flow signals are collected through an airway pressure sensor and a flow sensor, respectively, forming a multi-dimensional monitoring data stream. The multi-dimensional monitoring data stream covers oxygenation, ventilation and respiratory mechanics. S23. Filter, denoise and convert the collected raw monitoring signals to remove interference signals caused by coughing, talking and body position changes, so as to improve the accuracy and stability of the monitoring data. S24. Upload the processed standardized end-tidal carbon dioxide data, blood oxygen data, pressure and flow data to the central control unit in real time, and dynamically refresh and display them on the display interface simultaneously. S25. Store monitoring data at fixed time intervals to generate continuous dynamic carbon dioxide monitoring signals and physiological parameter trend curves, which can provide reliable data support for subsequent deviation calculation and feedback adjustment.

[0023] The working principle and effects of the above technical solution are as follows: High-frequency sampling of carbon dioxide partial pressure data improves the completeness of data capture and reduces the probability of missing parameter changes during the respiratory cycle. Simultaneous acquisition of multiple physiological signals to form a multi-dimensional monitoring data stream enhances the comprehensiveness of state perception and reduces the limitations of judgment caused by single signals. Filtering, denoising, and transforming the raw signals improves data accuracy and avoids monitoring distortion caused by external interference. Real-time uploading and refreshing of standardized data improves the convenience of operation and observation and reduces the risk of control delays. Storing data at fixed intervals and generating continuous signals and curves provides solid support for subsequent deviation calculations and completely preserves physiological changes during treatment, avoiding data gaps that affect control effects and improving the overall reliability of ventilation control.

[0024] In one embodiment of the present invention, S25 includes: Standardized monitoring data, collected and processed at fixed time intervals, are used to generate continuous time-series physiological parameter collection data. Continuous splicing processing is performed on the collected physiological parameter data to generate a complete and coherent dynamic carbon dioxide monitoring signal; The dynamic carbon dioxide monitoring signal is processed by curve conversion to generate a physiological parameter trend curve that intuitively reflects the changes in parameters; By correlating and integrating dynamic carbon dioxide monitoring signals with physiological parameter trend curves, a basic data set is generated to support subsequent calculations. The system transmits a set of basic data to the system's computing unit for use in subsequent deviation calculations and feedback adjustments.

[0025] The working principle and effects of the above technical solution are as follows: Collecting standardized monitoring data at fixed time intervals improves the orderliness of data processing and reduces the processing difficulty caused by scattered data. Continuous splicing of the collected data improves the coherence of monitoring signals and reduces misjudgments caused by data discontinuity. Curve conversion of monitoring signals enhances the intuitiveness of parameter changes and avoids abstract data affecting the efficiency of state judgment. Integrating signals and curves to form a basic data set improves the comprehensiveness of data support and reduces the risk of missing information in subsequent calculations. Transmitting the complete data set to the computing unit provides stable support for deviation calculation and reliable basis for feedback adjustment, avoiding control deviations due to insufficient data and improving the overall accuracy and smoothness of the ventilation control process.

[0026] In one embodiment of the present invention, step S3 includes: S31. The central control unit will compare the real-time measured value of end-tidal carbon dioxide partial pressure with the preset target value range of 35-45 mmHg point by point to accurately determine whether the current carbon dioxide level is low, normal or high. S32. Calculate the carbon dioxide deviation value ΔCO2 based on the measured value and the target value, and calculate the rate and direction of deviation change through continuous multi-period data to determine whether the carbon dioxide fluctuation is in a state of rapid rise, rapid fall or slow and stable. S33. Simultaneously identify external interference factors, including sudden changes in airway pressure, abnormal flow, and cough signals, and mark whether there is strong interference in the current ventilation status to avoid interference causing biased assessment distortion. S34. Combining the magnitude of the deviation, the trend of change and the state of interference, the patient's ventilation and carbon dioxide steady state are comprehensively classified into three control states: steady state, dynamic deviation and emergency deviation. S35. Generate standardized carbon dioxide deviation assessment results, determine whether adjustment is needed, the direction of adjustment and the priority of adjustment, and transmit the assessment results to the feedback adjustment module to provide a basis for the generation of control commands.

[0027] The working principle and effects of the above technical solution are as follows: Comparing the measured carbon dioxide value with the target range point by point improves the accuracy of state judgment and reduces control errors caused by level misjudgment. Calculating the deviation value and the direction of change rate enhances the detail of fluctuation perception and reduces the omission of parameter change trends. Simultaneously identifying external interference and marking the ventilation status improves the authenticity of the assessment results and avoids distortion of judgment caused by interference factors. Combining multiple types of information to complete the comprehensive classification of ventilation steady state improves the rationality of state classification and reduces the blindness of control strategy selection. Generating standardized assessment results and transmitting them to the corresponding modules provides a reliable basis for the generation of subsequent control commands and makes the control actions more targeted, avoiding physiological fluctuations caused by unfounded adjustments, and improving the overall safety and stability of the treatment process.

[0028] In one embodiment of the present invention, S34 includes: Integrate data related to the magnitude of deviations, complete the data aggregation and processing of deviations, and generate summary data of deviation characteristics. By combining deviation characteristics with data processing of trend-related information, the transmission calculation of trend information is completed, and trend transmission data is generated. By using trend transmission data to correlate content related to the state of disturbance, cross-integration of multi-dimensional information is completed to generate basic data for comprehensive evaluation. The comprehensive assessment baseline data is processed by hierarchical classification to classify and distinguish patient ventilation and carbon dioxide homeostasis, and generate homeostasis grading data; Based on steady-state hierarchical data, the control states are classified and divided, and three types of control states are output: steady-state, dynamic offset, and emergency offset.

[0029] The working principle and effects of the above technical solution are as follows: Integrating deviation data and completing its aggregation and processing improves the completeness of information summarization and reduces the analytical difficulty caused by data dispersion. Combining deviation characteristic processing with trend information enhances the accuracy of trend judgment and reduces errors in state prediction. Cross-integrating multi-dimensional information improves the comprehensiveness of the assessment basis and avoids judgment bias caused by single pieces of information. Performing steady-state hierarchical division and classification improves the clarity of state definition and reduces the ambiguity in the selection of control direction. Based on hierarchical data to classify control states, it provides clear guidance for subsequent adjustment actions and makes ventilation control more in line with the actual physiological state, avoiding physiological disturbances caused by blind adjustments, and improving the overall controllability and safety of the treatment process.

[0030] In one embodiment of the present invention, S35 includes: Integrate information related to the three types of control states, complete the normalization and processing of the state information, and generate the basic data for the evaluation results; Conduct adjustment demand analysis on the basic data of the assessment results to generate adjustment demand-related data; By combining data related to adjustment needs, the relevant content of adjustment direction is derived, and adjustment direction transmission data is generated; the adjustment direction transmission data is used to match the adjustment execution priority, and priority ranking data is generated. All data related to the evaluation results are transmitted to the feedback adjustment module to generate standardized carbon dioxide deviation evaluation results that can support the creation of control commands.

[0031] The working principle and effects of the above technical solution are as follows: Standardizing the processing of three types of control state information improves the standardization of data integration and reduces analytical obstacles caused by information clutter. Conducting adjustment demand analysis enhances the targeted nature of control judgments and reduces unnecessary parameter adjustments. Deducing the adjustment direction and matching execution priorities improves the rationality of the control process and avoids ventilation fluctuations caused by chaotic control sequences. Transmitting complete assessment data to the feedback control module improves the reliability of instruction generation and reduces information gaps in instruction generation. Generating standardized carbon dioxide deviation assessment results provides solid support for subsequent control instructions and makes ventilation regulation more aligned with physiological states, avoiding safety risks caused by illogical adjustments, and overall improving the accuracy and smoothness of treatment control.

[0032] In one embodiment of the present invention, step S4 includes: S41. Within the pre-oxygenation time window, based on the carbon dioxide deviation assessment results obtained from real-time monitoring, the optimal adjustment mode is automatically matched from four preset strategies: steady-state fine-tuning, dynamic tracking, emergency correction, and anti-disturbance. The duration of the pre-oxygenation time window is automatically calculated and generated based on the information of the first time window. S42. Perform adjustment actions according to the selected strategy, adjust ventilation parameters individually or in combination, including ventilation frequency, tidal volume and inspiratory-expiratory ratio, or control the amount of carbon dioxide supply through a proportional control valve, or adjust the volume of the dead chamber in the ventilation circuit to achieve precise adjustment of carbon dioxide level. S43. The real-time calculated feedback adjustment amount is weighted and fused with the initial ventilation setpoint to avoid patient discomfort or ventilation fluctuations caused by parameter mutations, and to ensure that the adjustment process is smooth, stable and controllable. S44. The fused adjustment parameters are converted into executable electrical control signals and sent to the gas mixer, ventilator main unit and carbon dioxide proportional valve respectively to ensure that the actuators respond quickly to the adjustment commands. S45. Generate the final dynamic carbon dioxide steady-state maintenance command, lock the current optimal ventilation and gas ratio parameters, continuously maintain the patient's end-tidal carbon dioxide partial pressure within the target physiological range, and form a stable isocarbonate control output.

[0033] The working principle and effects of the above technical solution are as follows: Automatic matching and optimization of the adjustment strategy based on deviation assessment results improves the speed of control response and reduces the lag in strategy selection. Combined adjustment of ventilation parameters and gas ratio enhances the accuracy of carbon dioxide reversion and reduces deviations from the target range. Weighted fusion of the adjustment amount and initial setpoint improves the stability of the adjustment process and avoids patient discomfort caused by parameter mutations. Converting the adjustment parameters into electrical control signals and issuing them for execution improves the efficiency of the mechanism's response and reduces command transmission losses. After confirming that the patient has reached isocarbonate hyperoxia steady state, the system generates and sends a "ready" signal to external anti-tumor treatment equipment, triggering the synchronous activation of chemotherapy, radiotherapy, or immunotherapy equipment, achieving precise timing coordination between ventilation therapy and anti-tumor therapy. Generating steady-state maintenance commands and locking in optimal parameters ensures both continuous and stable carbon dioxide partial pressure and guarantees the combined effect of hyperoxia and combined therapy, preventing physiological disturbances caused by control failure and improving the overall safety and controllability of the treatment.

[0034] In one embodiment of the present invention, S43 includes: Extract the feedback regulation amount obtained from real-time calculation, complete the aggregation and processing of regulation amount data, and generate regulation data to be fused. Extract initial ventilation setpoints, perform normalization processing on the setpoint data, and generate basic ventilation configuration data; perform weighted fusion processing on the adjustment data to be fused and the basic ventilation configuration data to generate weighted integrated ventilation data. The weighted integrated ventilation data is subjected to stability verification processing to filter out abnormal content related to parameter mutations and generate stable ventilation transition data. Continuous optimization processing is performed on the stable ventilation transition data to generate smooth ventilation control data that is adapted to subsequent conduction.

[0035] The working principle and effects of the above technical solution are as follows: Extracting and aggregating feedback adjustment values ​​improves the regularity of adjustment data and reduces fusion deviations caused by fragmented data. Regularizing initial ventilation setpoints enhances the standardization of basic configuration data and reduces control risks caused by chaotic setpoints. Weighted fusion of the two types of data improves the adaptability of ventilation parameters and prevents the adjustment value from deviating from the initial setting. Stability verification of the integrated data filters out abnormal parameter mutations, preventing sudden parameter changes from causing patient discomfort or ventilation fluctuations. Continuous optimization of transitional data generates smooth control data suitable for subsequent conduction and ensures a coherent and controllable adjustment process, reducing interruptions or pauses in control, thus improving the overall stability and safety of ventilation regulation and making patients more comfortable during treatment.

[0036] In one embodiment of the present invention, step S5 includes: S51. Continuously output hyperoxia mixed gas according to the dynamic carbon dioxide steady-state maintenance command, and continuously adjust the ventilation output to keep the patient's end-tidal carbon dioxide partial pressure stable within the range of 35-45 mmHg, forming a safe and controllable isocarbonate hyperoxia ventilation state. S52. Real-time monitoring of multi-dimensional safety boundary parameters throughout the process, including inhaled carbon dioxide concentration not exceeding 5%, end-tidal carbon dioxide partial pressure maintained within the safe range of 30-50 mmHg, blood oxygen saturation not lower than 90%, and airway pressure not exceeding the safety upper limit. S53. When the system detects that the parameters exceed the safe range and the automatic adjustment cannot correct them quickly, it will immediately trigger an audible and visual alarm and automatically downgrade from the fully automatic control mode to the semi-automatic mode or the basic safety ventilation mode to prevent the risk from escalating. S54. After confirming that the patient has reached isocarbonate hyperoxia steady state, the ready signal is generated and sent to the external anti-tumor treatment device. The ready signal is selected from at least one of the following: level signal, serial communication command, wireless communication message, medical device communication protocol message, or digital pulse signal. S55. Continuously cycle through the monitoring, comparison, and adjustment process until the preset treatment duration is reached. After treatment, gradually reduce the oxygen concentration and stop ventilation according to the procedure, and record complete treatment data for review and follow-up.

[0037] The working principle and effects of the above technical solution are as follows: By precisely controlling the ventilation output, the patient's end-tidal carbon dioxide can be stably maintained within the range of 35-45 mmHg, forming a safe and controllable isocarbonate hyperoxia ventilation state, improving the safety and standardization of treatment. Real-time monitoring of multi-dimensional safety parameters throughout the process can promptly detect abnormal parameters, reducing the possibility of risk escalation and avoiding physical discomfort or treatment risks caused by parameter exceeding limits. Automatic alarm triggering and downgrading the ventilation mode when abnormal parameters occur can effectively reduce the occurrence of safety accidents and prevent the spread of risks. Furthermore, by initiating ventilation support in advance within the pre-oxygenation time window, it ensures that the patient is already in an isocarbonate hyperoxia steady state when the anti-tumor treatment window arrives; after confirming the steady state, a "ready" signal is generated and sent to external anti-tumor treatment equipment, precisely triggering the synchronous activation of chemotherapy, radiotherapy, or immunotherapy equipment, achieving precise timing synergy between hyperoxia ventilation and anti-tumor treatment, maximizing the combined treatment effect, and reducing treatment ineffectiveness or reduced efficacy due to timing misalignment. Strictly matching the treatment sequence allows for precise synergy between hyperbaric oxygen ventilation and radiotherapy, chemotherapy, and immunotherapy, maximizing the combined treatment effect and reducing treatment ineffectiveness. Continuous monitoring and adjustment, along with complete recording of treatment data, ensures controllability throughout the treatment process, provides support for subsequent review and follow-up, and prevents hyperbaric oxygen therapy from becoming disconnected from combined treatments, thereby improving the overall reliability of the treatment.

[0038] In one embodiment of the present invention, S54 includes: Read the preset timing information in the synchronous combined treatment mode, complete the integration and processing of the timing information, and generate timing control guidance data; Based on the timing control guidance data, the ventilation actions are segmented and programmed to generate segmented ventilation control data that is adapted to the treatment process; The ventilation system is driven to operate continuously by segmented ventilation control data, generating stable ventilation output data that fits the timing schedule. The stable ventilation output data is synchronized with the chemotherapy infusion, radiotherapy, irradiation, and immunotherapy drug administration process to generate hyperoxia steady-state coverage data; after confirming that the patient has reached isocarbonic hyperoxia steady state, a ready signal is generated and sent to the external anti-tumor treatment device. The ready signal is selected from at least one of the following: level signal, serial communication command, wireless communication message, medical device communication protocol message, or digital pulse signal. By using hyperoxia steady-state coverage data to enhance the ventilatory support effect during treatment, ventilatory operation data adapted to the needs of synergistic treatment can be generated.

[0039] The working principle and effects of the above technical solution are as follows: Integrating the timing content of synchronous treatment to form guiding data can improve the regularity of the time arrangement and reduce coordination deviations caused by time period mismatches. Segmenting ventilation actions according to the timing content can enhance the fit between the ventilation rhythm and the treatment rhythm and reduce the disconnection between the two processes. Relying on segmented data to maintain stable equipment operation can improve the stability of ventilation output and reduce state fluctuations caused by intermittent gas supply. After confirming that the patient has reached isocarbonate hyperoxia steady state, the system actively generates and sends multi-form "ready" signals (such as TTL level, RS232 command, Bluetooth MESH broadcast, DICOM trigger message, etc.) to external anti-tumor treatment equipment, accurately triggering the chemotherapy pump, radiotherapy equipment, or immunotherapy infusion pump to start treatment synchronously, realizing seamless timing coordination between ventilation support and anti-tumor treatment. Completing the connection and matching between the ventilation process and various anti-tumor intervention processes can prolong the coverage duration of hyperoxia steady state and weaken the tolerance of tumor tissue. Strengthening ventilation support throughout the entire process can not only ensure that the ventilation rhythm matches the overall rhythm of combined treatment, but also deepen the coordination between different treatment methods, reduce the loss of efficacy caused by gaps in the connection, and steadily improve the effect of comprehensive intervention.

[0040] One embodiment of the present invention, such as Figure 2 As shown, a respiratory device for isocarbonate hyperventilation and high-concentration oxygen ventilation support for cancer patients to achieve the above-described method isocarbonate hyperventilation isocarbonate ... High-concentration oxygen supply unit, used to deliver oxygen at a concentration of 60%-100% to cancer patients; The end-tidal carbon dioxide monitoring unit is used to collect patients' end-tidal carbon dioxide partial pressure data in real time. The control unit is connected to the monitoring unit, receives monitoring data and compares it with a preset target value, and generates an adjustment command based on the comparison result. The preset target value is 35-45 mmHg. An execution unit, connected to the control unit, automatically adjusts ventilation parameters and / or the carbon dioxide content of the inhaled gas according to the adjustment command; Timing control unit, such as Figure 3 As shown, the device has built-in chemotherapy synchronization module, radiotherapy synchronization module, and immunotherapy synchronization module, which store time window parameters for different treatment modes, so that the ventilation therapy of the device can be implemented within the treatment cycle of radiotherapy, chemotherapy or immunotherapy for cancer patients and cover at least part of the treatment period; the timing control unit is configured to generate and send a ready signal to external anti-tumor treatment equipment after confirming that the patient has reached isocarbonate hyperoxia steady state.

[0041] The working principle of the above technical solution is as follows: This respiratory device achieves high-concentration oxygen supply and precise ventilation control through the coordinated operation of various functional units. While ensuring the patient's respiratory safety, it assists in ventilation support for cancer patients by utilizing a hyperoxia environment. The specific working principle is as follows: After the device is started, the high-concentration oxygen supply unit starts first, continuously delivering oxygen to the patient at a preset concentration of 60%-100%, quickly establishing a hyperoxia treatment environment and laying the foundation for subsequent combined treatment. At the same time, it completes the setting and locking of initial parameters to ensure stable and controllable oxygen supply. The end-tidal carbon dioxide monitoring unit starts working simultaneously, collecting end-tidal carbon dioxide partial pressure data during the patient's exhalation process in real time. It maintains high-frequency sampling throughout the process to avoid missing parameter changes. The collected raw data can be directly transmitted to the control unit without additional processing, ensuring the authenticity and continuity of the monitoring data and providing a reliable basis for subsequent control. The control unit, acting as the core hub, receives data from the end-tidal carbon dioxide monitoring unit in real time. It compares this data point-by-point with the preset target value of 35-45 mmHg, analyzing data deviations, trends, and fluctuations. Simultaneously, it combines this data with preset parameters from the timing control unit to determine if the current ventilation status meets treatment needs, thereby generating precise adjustment commands. The execution unit receives these commands from the control unit and automatically adjusts ventilation parameters, including ventilation frequency and airflow rate. It also controls carbon dioxide supplementation to prevent sudden parameter changes that could cause patient discomfort, ensuring a smooth and stable adjustment process. If abnormal parameters are detected, the unit automatically adjusts the adjustment strategy to ensure the stability of the ventilation process. The timing control unit, relying on a built-in chemotherapy, radiotherapy, and immunotherapy synchronization module, stores time window parameters for different treatment modes, precisely controlling the timing of ventilation therapy. This ensures that the steady-state period of hyperoxia ventilation is accurately matched with the patient's chemotherapy, radiotherapy, and immunotherapy periods, achieving synergistic coordination between ventilation therapy and anti-tumor treatment. This ensures that the hyperoxia environment can fully play its role in supporting ventilation in cancer patients. Throughout the entire process, all units operate in tandem. The control unit continuously receives monitoring data and adjusts its commands, while the execution units respond synchronously. This maintains the patient's end-tidal carbon dioxide level within the physiological range of 35-45 mmHg, creating a stable and safe isocarbonate hyperoxia ventilation environment. This ensures the patient's breathing comfort and enhances the overall combined treatment effect through ventilation support for cancer patients in a hyperoxia environment. At the same time, it avoids treatment risks caused by abnormal parameters, ensuring that the treatment process is safe, controllable, and traceable.

[0042] The effects of the above technical solutions are as follows: The high-concentration oxygen supply unit can stably output gradient high-purity oxygen, improving the hypoxic microenvironment of tumor lesions and reducing the proliferation of cancer cells due to hypoxia. The end-tidal carbon dioxide monitoring unit continuously captures physiological indicators throughout the respiratory process, improving the accuracy of acid-base status monitoring and reducing missed diagnoses of fluctuations in vital signs. The control unit completes real-time data comparison and command generation, improving the response speed of ventilation regulation and reducing control oversights caused by lag in manual intervention. The execution unit autonomously adjusts ventilation parameters and gas composition, enhancing the overall automation level and avoiding respiratory rhythm disorders caused by significant parameter changes. The timing control unit distinguishes the scheduling rules of various treatment times, bringing ventilation intervention and anti-tumor treatment closer together, maintaining physiological homeostasis during long-term treatment, amplifying the actual effect of combined treatment, reducing resistance problems caused by single treatments, and comprehensively improving the overall quality and operational stability of tumor adjuvant intervention.

[0043] Obviously, those skilled in the art can make various modifications and variations to this invention without departing from its spirit and scope. Therefore, if these modifications and variations fall within the scope of the claims of this invention and their equivalents, this invention also intends to include these modifications and variations.

Claims

1. A method for controlling ventilation support in cancer patients with isocarbonate hyperventilation and high-concentration oxygen, characterized in that, The method includes: S1. Deliver high concentrations of oxygen to cancer patients for hyperventilation therapy to generate an initial hyperoxia ventilation state. S2. Real-time acquisition of patients' end-tidal carbon dioxide partial pressure data to generate dynamic carbon dioxide monitoring signals; S3. Compare and analyze the dynamic carbon dioxide monitoring signal with the preset isocarbonic acid target value range to generate carbon dioxide deviation assessment results. S4. Within the pre-oxygenation time window before the start of the first time window related to anti-tumor treatment, ventilation support is automatically started, and ventilation parameters and / or carbon dioxide supplementation of inhaled gas are automatically adjusted through the closed-loop feedback control system so that the patient has reached isocarbonate hyperoxia steady state when the first time window arrives. S5. After confirming that the patient has reached the isocarbonate hyperoxia steady state, a ready signal is generated and sent to the external anti-tumor treatment device, and ventilation support is continuously maintained within the first time window so that the patient's end-tidal carbon dioxide partial pressure is always maintained within the physiological steady state range of 35-45 mmHg.

2. The method for controlling ventilation support in tumor patients with isocarbonate hyperventilation and high oxygen concentration according to claim 1, characterized in that, S1 includes: S11. Based on the basic information of the cancer patient, the system completes the preset and locking of personalized treatment parameters, sets the high concentration oxygen concentration in the range of 60%-100%, sets the target value of end-tidal carbon dioxide partial pressure in the normal physiological range of 35-45 mmHg, and selects the continuous mode, intermittent mode or synchronous combined treatment mode to complete the full parameter configuration before treatment. S12. Based on the patient's individualized physiological data and preset minute ventilation requirements, the initial ventilation parameters are automatically calculated and generated through the built-in algorithm of the control module. S13. Control the high-pressure oxygen source, air source and optional carbon dioxide source to enter the gas mixer in a preset ratio. After being humidified by the humidifier, the high concentration of oxygen is delivered to the patient through the inhalation circuit to establish the initial high oxygen ventilation state. S14. The system completes the gas path sealing check and sensor zero point calibration to ensure that the end-tidal carbon dioxide monitoring, blood oxygen monitoring, pressure monitoring and flow monitoring functions are all in normal working order, with no air leakage, pipe blockage or abnormal signal. S15. Record the patient's baseline vital signs data at the initial moment as a reference benchmark for subsequent adjustments and efficacy evaluation.

3. The method for controlling ventilation support in tumor patients with isocarbonate hyperventilation and high oxygen concentration according to claim 2, characterized in that, S12 includes: Extract individualized physiological data of patients, extract preset minute ventilation requirements, complete the fusion processing of the two types of information, and generate ventilation demand data to be calculated; The ventilation demand data to be calculated is imported into the built-in algorithm of the control module, and the numerical iteration processing inside the algorithm is completed to generate the basic calculation results of ventilation parameters. The basic calculation results of ventilation parameters are graded and filtered, retaining values ​​related to ventilation frequency and tidal volume to generate the first set of ventilation sub-parameters. Supplement the basic calculation results of ventilation parameters, obtain the relevant values ​​of the inspiratory-expiratory ratio and the relevant values ​​of the initial airway pressure threshold, and generate the second set of ventilation sub-parameters. Integrate the first group of ventilation sub-parameters with the second group of ventilation sub-parameters, complete the parameter combination and format unification, and generate initial ventilation parameters adapted to the patient's condition.

4. The method for controlling ventilation support in tumor patients with isocarbonate hyperventilation and high oxygen concentration according to claim 1, characterized in that, S2 includes: S21. Through a mainstream or bypass end-tidal carbon dioxide sensor, the end-tidal carbon dioxide partial pressure data of the patient during the exhalation process is collected in real time, and the dynamic change curve of carbon dioxide concentration during the respiratory cycle is fully captured. S22. Simultaneously collect the patient's blood oxygen saturation signal through the finger clip pulse oximeter, and collect real-time airway pressure, inspiratory and expiratory flow signals through the airway pressure sensor and flow sensor respectively, forming a multi-dimensional monitoring data stream; S23. Filter, denoise and convert the collected raw monitoring signals to remove interference signals caused by coughing, talking and changes in body position; S24. Upload the processed standardized end-tidal carbon dioxide data, blood oxygen data, pressure and flow data to the central control unit in real time, and dynamically refresh and display them on the display interface simultaneously. S25. Store monitoring data at fixed time intervals to generate continuous dynamic carbon dioxide monitoring signals and physiological parameter trend curves.

5. The method for controlling ventilation support in tumor patients with isocarbonate hyperventilation and high oxygen concentration according to claim 4, characterized in that, The S25 includes: Standardized monitoring data, collected and processed at fixed time intervals, are used to generate continuous time-series physiological parameter collection data. Continuous splicing processing is performed on the collected physiological parameter data to generate a complete and coherent dynamic carbon dioxide monitoring signal; The dynamic carbon dioxide monitoring signal is processed by curve conversion to generate a physiological parameter trend curve that intuitively reflects the changes in parameters; By correlating and integrating dynamic carbon dioxide monitoring signals with physiological parameter trend curves, a basic data set is generated to support subsequent calculations. The system transmits a set of basic data to the system's computing unit for use in subsequent deviation calculations and feedback adjustments.

6. The method for controlling ventilation support in tumor patients with isocarbonate hyperventilation and high oxygen concentration according to claim 1, characterized in that, The S3 includes: S31. The central control unit will compare the real-time measured value of end-tidal carbon dioxide partial pressure with the preset target value range of 35-45 mmHg point by point to determine whether the current carbon dioxide level is low, normal or high. S32. Calculate the carbon dioxide deviation value ΔCO2 based on the measured value and the target value, and calculate the rate and direction of deviation change through continuous multi-period data to determine whether the carbon dioxide fluctuation is in a state of rapid rise, rapid fall or slow and stable. S33. Simultaneously identify external interference factors and mark whether there is strong interference in the current ventilation status to avoid interference causing bias assessment distortion. S34. Combining the magnitude of the deviation, the trend of change and the state of interference, the patient's ventilation and carbon dioxide steady state are comprehensively classified into three control states: steady state, dynamic deviation and emergency deviation. S35. Generate standardized carbon dioxide deviation assessment results, determine whether adjustment is needed, the direction of adjustment and the priority of adjustment, and transmit the assessment results to the feedback adjustment module.

7. The method for controlling ventilation support in tumor patients with isocarbonate hyperventilation and high oxygen concentration according to claim 6, characterized in that, S34 includes: Integrate data related to the magnitude of deviations, complete the data aggregation and processing of deviations, and generate summary data of deviation characteristics. By combining deviation characteristics with data processing of trend-related information, the transmission calculation of trend information is completed, and trend transmission data is generated. By using trend transmission data to correlate content related to the state of disturbance, cross-integration of multi-dimensional information is completed to generate basic data for comprehensive evaluation. The comprehensive assessment baseline data is processed by hierarchical classification to classify and distinguish patient ventilation and carbon dioxide homeostasis, and generate homeostasis grading data; Based on steady-state hierarchical data, the control states are classified and divided, and three types of control states are output: steady-state, dynamic offset, and emergency offset.

8. The method for controlling ventilation support in tumor patients with isocarbonate hyperventilation and high oxygen concentration according to claim 1, characterized in that, The S4 includes: S41. Within the pre-oxygenation time window, based on the carbon dioxide deviation assessment results obtained from real-time monitoring, the optimal adjustment mode is automatically matched from four preset strategies: steady-state fine-tuning, dynamic tracking, emergency correction, and anti-disturbance. The duration of the pre-oxygenation time window is automatically calculated and generated based on the information of the first time window. S42. Perform adjustment actions according to the selected strategy, adjust ventilation parameters individually or in combination, or control the amount of carbon dioxide supply through the proportional control valve, or adjust the volume of the ineffective cavity in the ventilation circuit to achieve precise adjustment of carbon dioxide level. S43. The real-time calculated feedback adjustment amount is weighted and fused with the initial ventilation setpoint to avoid patient discomfort or ventilation fluctuations caused by parameter mutations. S44. The fused adjustment parameters are converted into executable electrical control signals and sent to the gas mixer, the ventilator main unit and the carbon dioxide proportional valve respectively. S45. Generate the final dynamic carbon dioxide steady-state maintenance command, lock the current optimal ventilation and gas ratio parameters, continuously maintain the patient's end-tidal carbon dioxide partial pressure within the target physiological range, and form a stable isocarbonate control output.

9. The method for controlling ventilation support in tumor patients with isocarbonate hyperventilation and high oxygen concentration according to claim 1, characterized in that, The S5 includes: S51. Continuously output hyperoxia mixed gas according to the dynamic carbon dioxide steady-state maintenance command, and continuously adjust the ventilation output to keep the patient's end-tidal carbon dioxide partial pressure stable within the range of 35-45 mmHg, forming a safe and controllable isocarbonate hyperoxia ventilation state. S52. Real-time monitoring of multi-dimensional safety boundary parameters throughout the entire process; S53. When the system detects that the parameters exceed the safe range and the automatic adjustment cannot correct them quickly, the system will immediately trigger an audible and visual alarm and automatically downgrade from the fully automatic control mode to the semi-automatic mode or the basic safety ventilation mode. S54. After confirming that the patient has reached a steady state of isocarbonate hyperoxia, a ready signal is generated and sent to the external anti-tumor treatment device. The ready signal is selected from at least one of the following: level signal, serial communication command, wireless communication message, medical device communication protocol message, or digital pulse signal. S55. The monitoring, comparison, and adjustment process is continuously executed in a loop until the preset treatment duration is reached. After the treatment is completed, the oxygen concentration is gradually reduced and ventilation is stopped according to the procedure. Complete treatment data is recorded for review and follow-up.

10. A respiratory device for implementing isocarbonate hyperventilation with high oxygen concentration for ventilating tumor patients according to claim 1, characterized in that, The breathing device includes: High-concentration oxygen supply unit, used to deliver oxygen at a concentration of 60%-100% to cancer patients; The end-tidal carbon dioxide monitoring unit is used to collect patients' end-tidal carbon dioxide partial pressure data in real time. The control unit is connected to the monitoring unit, receives monitoring data and compares it with a preset target value, and generates an adjustment command based on the comparison result. The preset target value is 35-45 mmHg. An execution unit, connected to the control unit, automatically adjusts ventilation parameters and / or the carbon dioxide content of the inhaled gas according to the adjustment command; The timing control unit has built-in chemotherapy synchronization module, radiotherapy synchronization module and immunotherapy synchronization module, which store time window parameters for different treatment modes, so that the ventilation therapy of the device can be implemented within the treatment cycle of radiotherapy, chemotherapy or immunotherapy for cancer patients and cover at least part of the treatment period; the timing control unit is configured to generate and send a ready signal to external anti-tumor treatment equipment after confirming that the patient has reached isocarbonate hyperoxia steady state.

Images